Treatment
Nimotuzumab clinical trials
We’re tracking 31 recruiting studies that include Nimotuzumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07706985RecruitingPhase 3
Immunotherapy for advanced nasopharyngeal cancer
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–70 - NCT04235114RecruitingPhase 1/Phase 2
PET scan test for EGFR-positive cancers using an antibody tracer
This study tests a special PET scan agent (an antibody tracer) to help doctors see EGFR-positive cancers without needing invasive procedures. It is mainly for early testing (Phase 1/2) to understand how well it works for imaging.
Saskatoon, SaskatchewanAges 18–80 - NCT06410651RecruitingPhase 2
Nimotuzumab with chemoradiation for advanced esophageal cancer
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
BeijingAges 18–80 - NCT06429839RecruitingPhase 2
Nimotuzumab with chemoradiation for esophageal cancer
This trial tests a drug called nimotuzumab combined with standard chemotherapy and radiation for patients with esophageal cancer. It may help improve treatment effectiveness for those whose cancer has not spread to other parts of the body.
BeijingAges 18–80 - NCT06722911RecruitingPhase 2
Adjuvant drug combo for EGFR-positive pancreatic cancer
This trial tests combining nimotuzumab with chemotherapy (nab-paclitaxel and gemcitabine) after surgery to prevent pancreatic cancer from returning. It is for people whose tumors have a protein called EGFR, and whose cancer was removed with clear or close margins.
Hangzhou, ZhejiangAges 18–75 - NCT07386704Enrolling by invitationPhase 2
Nimotuzumab with chemo and radiation for advanced pancreatic cancer
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT06676722RecruitingPhase 2
SBRT and two targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
Xiamen, FujianAges 18–75 - NCT07240766RecruitingPhase 2
New drug combo for KRAS G12D pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
Hangzhou, ZhejiangAges 18–75 - NCT05978050RecruitingPhase 3
Nimotuzumab plus paclitaxel for recurring stomach cancer
This Phase 3 trial tests whether adding nimotuzumab (an anti-EGFR antibody) to paclitaxel can improve outcomes for people with stomach or stomach-junction cancer that has returned and spread. It targets tumors with high EGFR (“EGFR high” on a pathology test) to see if this combination works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT04459065RecruitingPhase 1/Phase 2
Imaging medicine to help find lung cancer during surgery
This trial tests a special imaging drug (IRDye800CW-nimotuzumab) that may help surgeons better see lung cancer tissue during planned lung surgery. Phase 1/2 looks mainly at safety and how well the imaging works to guide the operation.
Saskatoon, SaskatchewanAges 18–80 - NCT05717790Recruiting
Nimotuzumab with chemo and radiation for advanced nose cancer
This trial tests whether adding nimotuzumab (an anti-EGFR antibody) to standard chemotherapy and radiation can improve outcomes for people with advanced nasopharyngeal carcinoma. It may help the cancer respond better and control it more effectively after treatment.
Baise City, GuangxiAges 18–70 - NCT06259721RecruitingPhase 2
New drug combo for advanced nasopharyngeal cancer after platinum failure
This trial tests a combination of three drugs—an anti-PD1 immunotherapy, nimotuzumab (targets EGFR), and capecitabine (chemotherapy)—for people whose nasopharyngeal cancer has returned or spread and no longer responds to platinum-based chemotherapy. The goal is to see if this combination can help when standard treatment stops working.
Nanchang, JiangxiAges 18–70 - NCT06389760RecruitingPhase 2
Nimotuzumab combo after pancreatic cancer surgery
This trial tests adding nimotuzumab (a targeted therapy) to standard chemotherapy for people whose pancreatic cancer was completely removed with surgery. The goal is to see if this combination helps prevent the cancer from coming back.
Nanjing, JiangsuAges 18 years+ - NCT07601737RecruitingPhase 2
Nimotuzumab with immunotherapy and chemotherapy for head and neck cancer
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
ShanghaiAges 18–75 - NCT06509009RecruitingPhase 2
Nimotuzumab and TGP for first-line recurrent / metastatic nasopharyngeal cancer
This trial tests a combination of two drugs—nimotuzumab (a targeted therapy) and TGP (a chemotherapy)—as a first treatment for people whose nasopharyngeal cancer has returned or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06718205RecruitingPhase 2
Nimotuzumab plus immunotherapy and chemo for esophageal cancer
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
Zhengzhou, HenanAges 18–75 - NCT06770452RecruitingPhase 2
HRS-4642 combo for first-line advanced pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Hangzhou, ZhejiangAges 18–75 - NCT06988956RecruitingPhase 2
Nimotuzumab Plus Chemoradiation for Older Adults with Esophageal Cancer
This trial tests adding nimotuzumab, a targeted therapy, to standard chemoradiation for elderly patients with esophageal squamous cell cancer. It aims to see if the combination improves outcomes.
NanjingAges 75 years+ - NCT07105592RecruitingPhase 1/Phase 2
Study of nimotuzumab plus adebrelimab with chemo for head and neck cancer patients who cannot take cisplatin
This trial tests a combination of two drugs (nimotuzumab and adebrelimab) along with chemotherapy for people with head and neck cancer that has returned or spread, and who cannot take the standard chemo drug cisplatin. The goal is to see if this combination works and is safe for these patients.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07333274RecruitingPhase 3
Radiation plus nimotuzumab for head and neck cancer
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
Shandong, ProvinceAges 18 years+ - NCT07353723RecruitingPhase 2
Combination therapy for advanced tonsil cancer
This trial tests a combination of two targeted drugs (nimotuzumab and toripalimab) with chemotherapy for people with advanced tonsil cancer that can be surgically removed. The goal is to see if this approach works better than standard treatment.
Shanxi, ProvinceAges 18–80 - NCT07445048RecruitingPhase 3
Radiation, targeted therapy, and immunotherapy for high-risk head and neck cancer
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
ShanghaiAges 18 years+ - NCT07457528RecruitingPhase 2
Chemo, radiation, and immune therapy before surgery for esophageal cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07312578Enrolling by invitationPhase 2
Targeted drugs plus chemo before surgery for esophageal cancer
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–70
What Nimotuzumab is being studied for
Conditions with recruiting Nimotuzumab studies.
Common questions
- Are there clinical trials studying Nimotuzumab?
- Yes. Clin2 currently lists 31 recruiting studies that include Nimotuzumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Nimotuzumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Nimotuzumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Nimotuzumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.